Status: Recruiting
A Prospective, Experimental, Multicenter, Open-label, Randomized, Controlled Trial of 3-month Dual Antiplatelet Therapy Followed by Ticagrelor Versus 6-month Dual Antiplatelet Therapy Followed by Ticagrelor After Implanting Bridge
To compare the incidence of the composite endpoints of non-fatal ischaemic stroke, transient ischaemia (TIA) and all-cause mortality at 12-month follow-up after implantation of Bridge for the treatment of symptomatic vertebral artery stenosis in subjects who had been taking different durations of dual-antiplatelet therapy (3 vs 6 months) and ticagrelor monotherapy.
Participants needed: 560
Trial details
Age: 18-80Biological sex: AllType: InterventionalSponsor: The Fourth Affiliated Hospital of China Medical UniversityUpdated: Mar 8, 2024Locations: 1
Eligibility criteria
Patients who are suitable for Bridge implantation [+3]
mRS≥3 [+9]